Rivaroxaban

ApprovedCompleted

0 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Antiphospholipid Antibody Syndrome

Conditions

Antiphospholipid Antibody Syndrome

Trial Timeline

Sep 1, 2014 → Sep 30, 2017

NCT ID

NCT02116036

About Rivaroxaban

Rivaroxaban is a approved stage product being developed by Bayer for Antiphospholipid Antibody Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT02116036. Target conditions include Antiphospholipid Antibody Syndrome.

What happened to similar drugs?

1 of 1 similar drugs in Antiphospholipid Antibody Syndrome were approved

Approved (1) Terminated (0) Active (0)

✅Apixaban + WarfarinBristol Myers SquibbApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (7)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04416048	Phase 2	Terminated	Nov 30, 2020	Jul 20, 2021	COVID-19
NCT04096547	Pre-clinical	UNKNOWN	Sep 25, 2019	Aug 30, 2022	Atrial Fibrillation
NCT03772457	Pre-clinical	UNKNOWN	Jan 18, 2019	Dec 31, 2024	Cerebrovascular Stroke
NCT02387229	Phase 3	Terminated	Mar 1, 2015	May 18, 2024	ATRIAL FIBRILLATION
NCT02116036	Approved	Completed	Sep 1, 2014	Sep 30, 2017	Antiphospholipid Antibody Syndrome
NCT01464450	Phase 1	Completed	Oct 1, 2011	Dec 1, 2011	Pharmacokinetics
NCT01094886	Phase 3	Completed	Mar 1, 2010	Dec 1, 2010	Arthritis

Competing Products

4 competing products in Antiphospholipid Antibody Syndrome

See all competitors

Product	Company	Stage	Hype Score
RAY121	Chugai Pharmaceutical	Phase 1	36
RAY121	Chugai Pharmaceutical	Phase 1	36
Crovalimab + Placebo + VKA	Roche	Phase 2	27
Apixaban + Warfarin	Bristol Myers Squibb	Approved	43